Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
Oncology
-
-
Crescent and Kelun-Biotech swap cancer asset rights in double deal
US company Crescent Biopharma and China-based Kelun-Biotech have partnered to exchange the rights to two of their cancer drugs as…
-
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene…
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash…
-
General Proximity and Daiichi Sankyo link on oncology
General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. Daiichi…
-
AI breakthrough promises earlier prostate cancer diagnosis
According to Cancer Research UK, prostate cancer is the most common cancer among men in the UK, representing 28% of…
-
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
18 October 2025 marked the presentation of the highly anticipated OptiTROP-Breast02 trial at the 2025 European Society for Medical Oncology…
-
ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC
On 18 October 2025 at the European Society of Medical Oncology, held in Berlin, Germany, from 17 to 21 October,…
-
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets for the identification and development…
